BNX13
2021-11-16
Pls like
Pfizer to allow generic versions of its COVID-19 pill in 95 countries<blockquote>辉瑞将允许其COVID-19药物的仿制药在95个国家/地区上市</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":871629601,"tweetId":"871629601","gmtCreate":1637066332543,"gmtModify":1637066332912,"author":{"id":4098068058321510,"idStr":"4098068058321510","authorId":4098068058321510,"authorIdStr":"4098068058321510","name":"BNX13","avatar":"https://static.tigerbbs.com/5d3344dbee36ba1a93ce6095b9a6a82b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/871629601","repostId":1142799154,"repostType":4,"repost":{"id":"1142799154","kind":"news","pubTimestamp":1637065694,"share":"https://www.laohu8.com/m/news/1142799154?lang=zh_CN&edition=full","pubTime":"2021-11-16 20:28","market":"us","language":"en","title":"Pfizer to allow generic versions of its COVID-19 pill in 95 countries<blockquote>辉瑞将允许其COVID-19药物的仿制药在95个国家/地区上市</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142799154","media":"Reuters","summary":"Pfizer Inc(PFE.N)said on Tuesday it will allow generic manufacturers to supply its experimental anti","content":"<p>Pfizer Inc(PFE.N)said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).</p><p><blockquote>辉瑞公司（PFE.N）周二表示，将允许仿制药制造商通过与国际公共卫生组织药品专利池（MPP）的许可协议向95个中低收入国家供应其实验性抗病毒新冠肺炎药丸。</blockquote></p><p> The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.</p><p><blockquote>辉瑞和MPP之间的自愿许可协议将允许联合国支持的组织向合格的仿制药制造商授予分许可，以生产他们自己版本的PF-07321332。辉瑞将以Paxlovid品牌销售其生产的药丸。</blockquote></p><p> Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, has said the pill cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial.The drug will be used in combination with ritonavir, an HIV drug that is already available generically.</p><p><blockquote>辉瑞公司也生产最广泛使用的COVID-19疫苗之一，该公司表示，在其临床试验中，该药物将有严重疾病风险的成年人住院或死亡的几率降低了89%。该药物将与利托那韦联合使用，利托那韦是一种已经上市的HIV药物。</blockquote></p><p> Pfizer's licensing deal follows a similar arrangement by rival Merck & Co(MRK.N)for generic manufacturing of its COVID-19 treatment. The deals are unusual arrangements that acknowledge the dire need for effective treatments as well as the pressure drugmakers are under to make their life saving drugs accessible at very low costs.</p><p><blockquote>辉瑞的许可协议是在竞争对手默克公司（MRK）做出类似安排之后达成的。N）用于其COVID-19治疗的仿制药生产。这些交易是不同寻常的安排，承认了对有效治疗的迫切需求，以及制药商面临的以极低成本提供救命药物的压力。</blockquote></p><p> \"We are extremely pleased to have another weapon in our armoury to protect people from the ravages of COVID-19,\" Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.</p><p><blockquote>药品专利池执行董事查尔斯·戈尔(Charles Gore)在接受采访时表示：“我们非常高兴在我们的军械库中拥有另一件武器来保护人们免受COVID-19的蹂躏。”</blockquote></p><p> Gore said he hoped the generic version of Pfizer's drug will be available within months.</p><p><blockquote>戈尔说，他希望辉瑞药物的仿制药能在几个月内上市。</blockquote></p><p> The 95 countries in the license agreement cover around 53% of the world's population and include all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.</p><p><blockquote>许可协议中的95个国家覆盖了约53%的世界人口，包括所有低收入和中低收入国家以及撒哈拉以南非洲的一些中上收入国家。辉瑞和MPP表示，它们还包括在过去五年中从中下收入过渡到中上收入状态的国家。</blockquote></p><p> \"We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections... We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs,\" Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>“我们相信口服抗病毒治疗可以在降低COVID-19感染的严重程度方面发挥至关重要的作用……我们必须努力确保所有人——无论他们居住在哪里或情况如何——都能获得这些突破，”辉瑞首席执行官阿尔伯特·布尔拉在一份声明中表示。</blockquote></p><p> Pfizer will waive royalties on sales in low-income countries. It will also waive them in the other countries covered by the agreement as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organization.</p><p><blockquote>辉瑞将免除在低收入国家销售的特许权使用费。只要新冠肺炎仍被世界卫生组织列为国际关注的突发公共卫生事件，它还将在协议涵盖的其他国家豁免这些措施。</blockquote></p><p> Pfizer's version of the drug will be in high demand. The company has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.</p><p><blockquote>辉瑞的药物版本将会有很高的需求。该公司表示，预计到下个月底将生产18万个疗程，到2022年底至少生产5000万个疗程。</blockquote></p><p> Even so, the drugmaker could be stretched trying to supply 47% of the world's population. A Pfizer executive said last week the market for the drug might be up to 150 million people and that many countries might also be interested in buying doses for their strategic reserves.</p><p><blockquote>即便如此，这家制药商在为世界47%的人口供货时可能会捉襟见肘。辉瑞的一位高管上周表示，该药物的市场可能高达1.5亿人，许多国家也可能有兴趣购买其战略储备剂量。</blockquote></p><p> Pfizer has said it will sell the supply it produces using a tiered pricing approach based on the income level of each country. In the United States, it expects to price its treatment close to where Merck has priced its drug at around $700 a course.</p><p><blockquote>辉瑞表示，将根据每个国家的收入水平，采用分级定价方式销售其生产的产品。在美国，该公司预计其治疗价格接近默克公司每疗程700美元左右的药物定价。</blockquote></p><p> Merck has license agreements for it COVID-19 pill, molnupiravir, in over 100 countries. Still, some international health officials said even that is not enough for the medicine to reach many in low- and middle-income countries in large enough numbers.</p><p><blockquote>默克公司在100多个国家拥有其COVID-19药丸molnupiravir的许可协议。尽管如此，一些国际卫生官员表示，即使这样也不足以让中低收入国家的许多人获得足够多的药物。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to allow generic versions of its COVID-19 pill in 95 countries<blockquote>辉瑞将允许其COVID-19药物的仿制药在95个国家/地区上市</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to allow generic versions of its COVID-19 pill in 95 countries<blockquote>辉瑞将允许其COVID-19药物的仿制药在95个国家/地区上市</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-16 20:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer Inc(PFE.N)said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).</p><p><blockquote>辉瑞公司（PFE.N）周二表示，将允许仿制药制造商通过与国际公共卫生组织药品专利池（MPP）的许可协议向95个中低收入国家供应其实验性抗病毒新冠肺炎药丸。</blockquote></p><p> The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.</p><p><blockquote>辉瑞和MPP之间的自愿许可协议将允许联合国支持的组织向合格的仿制药制造商授予分许可，以生产他们自己版本的PF-07321332。辉瑞将以Paxlovid品牌销售其生产的药丸。</blockquote></p><p> Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, has said the pill cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial.The drug will be used in combination with ritonavir, an HIV drug that is already available generically.</p><p><blockquote>辉瑞公司也生产最广泛使用的COVID-19疫苗之一，该公司表示，在其临床试验中，该药物将有严重疾病风险的成年人住院或死亡的几率降低了89%。该药物将与利托那韦联合使用，利托那韦是一种已经上市的HIV药物。</blockquote></p><p> Pfizer's licensing deal follows a similar arrangement by rival Merck & Co(MRK.N)for generic manufacturing of its COVID-19 treatment. The deals are unusual arrangements that acknowledge the dire need for effective treatments as well as the pressure drugmakers are under to make their life saving drugs accessible at very low costs.</p><p><blockquote>辉瑞的许可协议是在竞争对手默克公司（MRK）做出类似安排之后达成的。N）用于其COVID-19治疗的仿制药生产。这些交易是不同寻常的安排，承认了对有效治疗的迫切需求，以及制药商面临的以极低成本提供救命药物的压力。</blockquote></p><p> \"We are extremely pleased to have another weapon in our armoury to protect people from the ravages of COVID-19,\" Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.</p><p><blockquote>药品专利池执行董事查尔斯·戈尔(Charles Gore)在接受采访时表示：“我们非常高兴在我们的军械库中拥有另一件武器来保护人们免受COVID-19的蹂躏。”</blockquote></p><p> Gore said he hoped the generic version of Pfizer's drug will be available within months.</p><p><blockquote>戈尔说，他希望辉瑞药物的仿制药能在几个月内上市。</blockquote></p><p> The 95 countries in the license agreement cover around 53% of the world's population and include all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.</p><p><blockquote>许可协议中的95个国家覆盖了约53%的世界人口，包括所有低收入和中低收入国家以及撒哈拉以南非洲的一些中上收入国家。辉瑞和MPP表示，它们还包括在过去五年中从中下收入过渡到中上收入状态的国家。</blockquote></p><p> \"We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections... We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs,\" Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>“我们相信口服抗病毒治疗可以在降低COVID-19感染的严重程度方面发挥至关重要的作用……我们必须努力确保所有人——无论他们居住在哪里或情况如何——都能获得这些突破，”辉瑞首席执行官阿尔伯特·布尔拉在一份声明中表示。</blockquote></p><p> Pfizer will waive royalties on sales in low-income countries. It will also waive them in the other countries covered by the agreement as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organization.</p><p><blockquote>辉瑞将免除在低收入国家销售的特许权使用费。只要新冠肺炎仍被世界卫生组织列为国际关注的突发公共卫生事件，它还将在协议涵盖的其他国家豁免这些措施。</blockquote></p><p> Pfizer's version of the drug will be in high demand. The company has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.</p><p><blockquote>辉瑞的药物版本将会有很高的需求。该公司表示，预计到下个月底将生产18万个疗程，到2022年底至少生产5000万个疗程。</blockquote></p><p> Even so, the drugmaker could be stretched trying to supply 47% of the world's population. A Pfizer executive said last week the market for the drug might be up to 150 million people and that many countries might also be interested in buying doses for their strategic reserves.</p><p><blockquote>即便如此，这家制药商在为世界47%的人口供货时可能会捉襟见肘。辉瑞的一位高管上周表示，该药物的市场可能高达1.5亿人，许多国家也可能有兴趣购买其战略储备剂量。</blockquote></p><p> Pfizer has said it will sell the supply it produces using a tiered pricing approach based on the income level of each country. In the United States, it expects to price its treatment close to where Merck has priced its drug at around $700 a course.</p><p><blockquote>辉瑞表示，将根据每个国家的收入水平，采用分级定价方式销售其生产的产品。在美国，该公司预计其治疗价格接近默克公司每疗程700美元左右的药物定价。</blockquote></p><p> Merck has license agreements for it COVID-19 pill, molnupiravir, in over 100 countries. Still, some international health officials said even that is not enough for the medicine to reach many in low- and middle-income countries in large enough numbers.</p><p><blockquote>默克公司在100多个国家拥有其COVID-19药丸molnupiravir的许可协议。尽管如此，一些国际卫生官员表示，即使这样也不足以让中低收入国家的许多人获得足够多的药物。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-allow-generic-versions-its-covid-19-pill-95-countries-2021-11-16/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-allow-generic-versions-its-covid-19-pill-95-countries-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142799154","content_text":"Pfizer Inc(PFE.N)said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).\nThe voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.\nPfizer, which also makes one of the mostly widely used COVID-19 vaccines, has said the pill cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial.The drug will be used in combination with ritonavir, an HIV drug that is already available generically.\nPfizer's licensing deal follows a similar arrangement by rival Merck & Co(MRK.N)for generic manufacturing of its COVID-19 treatment. The deals are unusual arrangements that acknowledge the dire need for effective treatments as well as the pressure drugmakers are under to make their life saving drugs accessible at very low costs.\n\"We are extremely pleased to have another weapon in our armoury to protect people from the ravages of COVID-19,\" Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.\nGore said he hoped the generic version of Pfizer's drug will be available within months.\nThe 95 countries in the license agreement cover around 53% of the world's population and include all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.\n\"We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections... We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs,\" Pfizer Chief Executive Albert Bourla said in a statement.\nPfizer will waive royalties on sales in low-income countries. It will also waive them in the other countries covered by the agreement as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organization.\nPfizer's version of the drug will be in high demand. The company has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.\nEven so, the drugmaker could be stretched trying to supply 47% of the world's population. A Pfizer executive said last week the market for the drug might be up to 150 million people and that many countries might also be interested in buying doses for their strategic reserves.\nPfizer has said it will sell the supply it produces using a tiered pricing approach based on the income level of each country. In the United States, it expects to price its treatment close to where Merck has priced its drug at around $700 a course.\nMerck has license agreements for it COVID-19 pill, molnupiravir, in over 100 countries. Still, some international health officials said even that is not enough for the medicine to reach many in low- and middle-income countries in large enough numbers.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":706,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/871629601"}
精彩评论